Core Insights - Evogene Ltd. will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025 [1] - The presentation will focus on the strategic emphasis on ChemPass AI, a proprietary generative AI technology for small molecule discovery and optimization in pharmaceuticals and agriculture [2] - One-on-one meetings will be available for interested investors and companies during the conference [3] Company Overview - Evogene Ltd. is an AI-driven discovery and development company specializing in novel small molecules for the pharmaceutical and agricultural chemical industries [4] - The company's innovation is centered around ChemPass AI, designed to create highly potent small molecules while addressing challenges in discovery and optimization [4] - Evogene aims to enhance the probability of success and reduce development costs through its technology, which supports both strategic partnerships and internal product pipelines [4]

Core Insights - Evogene Ltd. is undergoing a transformative phase focused on its ChemPass AI platform for AI-driven discovery and optimization of small molecules, targeting the pharmaceutical and agricultural markets [3][11]. Financial Performance - For the first half of 2025, total revenues were approximately $3.2 million, up from $2.3 million in the same period of 2024, primarily due to increased seed sales from Casterra [8][15]. - Total operating expenses for the first half of 2025 were approximately $7.7 million, a decrease from $11.1 million in the first half of 2024, attributed to reduced activities in subsidiaries [8][20]. - The net loss for the first half of 2025 was approximately $7.7 million, compared to $9.8 million in the same period last year, reflecting decreased operating expenses and increased financing income [8][23]. Strategic Developments - The company launched version 1.0 of its generative AI foundation model in partnership with Google Cloud, trained on a dataset of approximately 38 billion molecular structures [5]. - A collaboration with Tel Aviv University was announced to discover small molecule therapeutics for metabolic diseases, marking the start of a broader pharmaceutical ecosystem [6]. - Evogene is integrating AgPlenus' activities into its operations, which includes a 40% workforce reduction at AgPlenus to enhance operational efficiency [7]. Cash Position and Financing - As of June 30, 2025, Evogene had a cash balance of approximately $11.7 million, with cash usage during the second quarter of 2025 at approximately $2.4 million [12]. - The company raised $4.4 million through its existing at-the-market facility in June 2025, reflecting strong market confidence [10]. Operational Focus - The company is streamlining operations and focusing on enhancing ChemPass AI as its core engine, expanding strategic collaborations in pharmaceuticals, and optimizing agricultural offerings [9][14]. - Evogene executed a 30% workforce reduction, with cost savings expected to be realized from the third quarter of 2025 onwards [13].

Core Insights - Evogene Ltd. has entered a scientific collaboration with Professor Ehud Gazit's research group from Tel Aviv University to develop novel small molecules aimed at inhibiting pathological self-assembly processes associated with diseases like Tyrosinemia and Gout [1][3][5] Company Overview - Evogene Ltd. is a computational biology and chemistry company that utilizes big data and artificial intelligence to enhance the development of life-science products, aiming to increase success rates while reducing time and costs [6][7] Collaboration Details - The partnership will leverage Evogene's ChemPass AI technology, which focuses on generative molecular design, combined with Professor Gazit's expertise in molecular self-assembly [4][5] - The collaboration aims to create therapeutics that specifically target the self-assembly of small metabolites, potentially benefiting millions of patients suffering from related diseases [3][5] Technological Capabilities - Evogene has developed three tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focusing on different aspects of product development [7] - ChemPass AI will be utilized to drive generative molecular design, creating novel molecules tailored for therapeutic efficacy [7]

Company Overview - Evogene Ltd. is a computational biology company focused on revolutionizing life-science product discovery and development through big data and artificial intelligence [3][4] - The company has established three unique tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each targeting different core components for product development [4] Upcoming Financial Results - Evogene will release its financial results for the first quarter of 2025 on August 19, 2025 [1] - A conference call to discuss these results will be held at 9:00 AM Eastern Time on the same day [2] Strategic Partnerships and Subsidiaries - Evogene collaborates with various subsidiaries to develop products, including: - Biomica Ltd. focuses on microbiome-based therapeutics [5] - Lavie Bio Ltd. works on microbiome-based ag-biologicals [5] - AgPlenus Ltd. develops next-generation agricultural chemicals [5] - Casterra Ag Ltd. markets superior castor seed varieties for biofuel and other industries [5]

Core Insights - Evogene Ltd. has completed its generative AI foundation model, version 1.0, for small molecule design, developed in collaboration with Google Cloud, addressing the challenge of identifying novel small molecules for pharmaceutical and agricultural applications [1][6] - The new model enhances the capabilities of ChemPass AI by enabling simultaneous consideration of multiple complex product requirements, which is crucial for innovation and securing intellectual property [3][4] Company Developments - The foundation model achieves approximately 90% precision in novel molecule designs, a significant improvement over traditional methods which have around 29% precision [4] - The model is built on a dataset of approximately 38 billion molecular structures and utilizes Google Cloud's advanced AI infrastructure, ensuring scalability for future enhancements [5] - Evogene is already working on version 2.0 of its generative AI model, focusing on enhanced flexibility for multi-parameter optimization tailored to specific therapeutic and agricultural needs [6] Industry Implications - The generative AI model is expected to reduce late-stage failures in pharmaceutical R&D and facilitate the development of effective, sustainable, and proprietary agricultural chemicals [6] - The model's ability to create novel, patentable molecules positions Evogene to significantly impact drug discovery and agricultural product development [3][6]

Core Insights - Evogene Ltd. is set to release its financial results for Q1 2025 on May 21, 2025, followed by a conference call to discuss these results [1][2] Company Overview - Evogene Ltd. is a computational biology company that utilizes big data and artificial intelligence to innovate life-science product development, aiming to enhance success rates while minimizing development time and costs [3] - The company has established three unique technology engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focusing on different core components: microbes, small molecules, and genetic elements respectively [4] Subsidiaries and Focus Areas - Evogene operates four subsidiaries: 1. Biomica Ltd. focuses on microbiome-based therapeutics for human disorders using MicroBoost AI [6] 2. Lavie Bio Ltd. develops microbiome-based agricultural biologicals powered by MicroBoost AI [6] 3. AgPlenus Ltd. is engaged in developing next-generation agricultural chemicals for sustainable crop protection using ChemPass AI [6] 4. Casterra Ag Ltd. specializes in high-yield castor seed varieties for biofuel and other industries, utilizing GeneRator AI [6]